Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

NCT01111019 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators